Two Zoledronate Infusions May Cut Spine Fractures. One Is Less Certain
A 10-year trial suggests two zoledronate infusions may reduce spine fractures seen on X-rays after menopause. The verdict on one infusion is less certain.
Table of Contents
DISCLAIMER
This article is for informational purposes only and does not constitute medical advice. The statements in this article have not been evaluated by the FDA. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Consult your physician before starting any supplement or health protocol.
At the 10-year mark of a New Zealand trial, spine X-rays showed a new fracture in 22 women assigned two zoledronate infusions and 39 women assigned two placebo infusions. The result matters for women in their 50s who are weighing how early to address bone loss after menopause, especially if they encounter the claim that a single infusion could protect them for a decade. That group had 23 women with a new fracture, almost the same count as the two-infusion group, but its result was less conclusive under the trial’s statistical plan. Original randomized trial
Who enrolled in the decade-long trial
Mark Bolland and colleagues recruited 1,054 postmenopausal women aged 50 to 60. The average participant was 56 at enrollment. To qualify, a woman needed a bone mineral density T-score between −2.5 and zero at one or more of the scanned sites, which included the lumbar spine, femoral neck and total hip. That range included some readings considered normal as well as readings in the osteopenia range. The researchers also excluded women with a previous clinically recognized spine or hip fracture. The study therefore reached into a part of midlife where a scan may show some bone loss before a major fracture brings it to attention. Trial report and eligibility details
Each woman was randomly assigned to one of three groups. One group received active drug at enrollment and again five years later. Another received active drug at enrollment and placebo at year five. The third received placebo both times. The double-blind design helped keep expectations about treatment from influencing what participants reported or how the study was conducted. More than 95% of participants completed 10 years of follow-up. That matters when the endpoint depends on comparing images taken years apart. If many people miss the later visit, a trial can lose the measurements needed to tell how often the outcome occurred. Trial report
The three groups gave the researchers a way to ask whether an effect from an initial infusion might still be visible years later and whether a plan that included a second infusion could reduce fractures over the full decade. Those are distinct questions. An effect still visible in the group assigned one infusion would suggest a durable benefit under the conditions studied. A useful comparison of one versus two infusions would also need to estimate how much the second infusion adds, with enough precision to distinguish a meaningful difference from chance.
What counted as a spine fracture
The trial’s main outcome was a new vertebral fracture identified by a change in the shape of a bone in the spine. A radiologist compared side-view X-rays taken at enrollment, five years and ten years. The assessment considered how the shape of a vertebra changed, including a change in height of at least 20%. A vertebra that compresses may look shorter or wedge-shaped on a later image. Because the researchers took X-rays at scheduled visits, they could find changes even in participants who had never sought care for an episode of back pain. Methods and imaging criteria
A fracture found this way can matter even when it causes few noticeable symptoms. It also answers a specific question about the condition of the spine on an image. If you want to know how often women experienced a painful fracture, needed assistance at home or were admitted to hospital, you need information about those outcomes. The investigators collected reports of clinical fractures at six-month intervals and checked them against radiology reports. That separate method matters because a scheduled X-ray can detect a fracture that a participant would have had no reason to report. Fracture ascertainment methods
The same distinction matters for hip fractures. The study included a broader measure that pooled fractures of the hip with fractures at sites including the wrist, spine, shoulder and pelvis. A reduction in that combined outcome can reflect fractures avoided at several sites, or a reduction concentrated at one of them. It takes a site-specific estimate to say how much an intervention may change the chance of breaking a hip. The strongest result in this trial concerns the shape of the vertebrae, measured with the same type of imaging across the three groups. Trial outcomes and definitions
Why 22 and 23 led to different conclusions
Over ten years, 6.3% of women assigned two active infusions had a new vertebral fracture on imaging, compared with 11.1% in the placebo group. That observed gap was 4.8 percentage points, or roughly five fewer women with a fracture per 100 assigned to the active group in this trial. The relative estimate was a 44% reduction, with a 95% confidence interval that ranged from an 8% to a 66% reduction. The absolute figures put the outcome in familiar terms. The confidence interval shows how much uncertainty still surrounds the size of the possible benefit. Primary trial results
In the group assigned one active infusion, 6.6% had a new vertebral fracture. That was 4.5 percentage points below placebo and close to the two-infusion result. The one-infusion comparison missed the criterion for statistical significance under the primary analysis plan. The paper reports a nominal 95% confidence interval and an adjusted P value, which can look contradictory because they address the comparison differently. With two active groups compared against placebo, the trial’s statistical adjustment accounted for the extra chance of a positive result when making more than one comparison. The adjusted P value for the single-infusion group was 0.08. Primary trial results
The difference between 22 and 23 is one woman. Those counts leave room for several possibilities, including a real benefit from one infusion and an additional benefit from a second that the study could only estimate imprecisely. The comparison against placebo cleared the trial’s statistical threshold for the two-infusion group. Establishing that the two schedules perform similarly would take a comparison designed to rule out a clinically important difference between them. That distinction is especially relevant when the proposed trade-off is one fewer infusion in exchange for accepting some uncertainty about fracture risk.
Why the difference was clearer in years five to ten
Zoledronate is a bisphosphonate that binds to bone mineral. When osteoclasts, the cells that remove old bone, work on a surface containing the drug, it can interfere with an enzyme they need to function. Slowing bone resorption may help preserve bone density after menopause. Binding to bone also offers a biological reason to test whether an infusion can keep influencing bone turnover after the drug has largely cleared from circulation. The mechanism makes a durable effect plausible, while the duration of meaningful fracture protection has to be measured in people. FDA prescribing information
In a secondary analysis of the same trial, the investigators looked at the first and second five-year periods separately. The difference in X-ray-detected vertebral fractures was clearer in years five to ten. Relative to placebo, the estimated reduction in that second period was 58% in the group assigned two active infusions and 57% in the group assigned one. The timing is particularly interesting in the latter group because those participants received placebo at year five. The pattern is consistent with a sustained effect from the initial infusion. It comes from another analysis of the same participants, so its value is in showing when the original groups separated. Secondary analysis of fracture timing
There are two reasons to be careful about turning the year-five boundary into a biological timetable. An X-ray at a scheduled visit can show that a vertebra changed since the previous image, while the exact date of the change may be unknown. And dividing a decade of follow-up into two periods leaves fewer fractures in each comparison, making the individual estimates less precise. The later separation could reflect a benefit that accumulates as untreated bone loss progresses, an increase in underlying fracture risk over time, or both. The analysis can suggest those explanations without establishing how much each contributed. Secondary analysis and discussion
How far the findings travel beyond this group
An earlier New Zealand trial helps put the absolute numbers in context. In that study, 2,000 women aged 65 or older with osteopenia at the hip were followed for six years. A fragility fracture occurred in 122 women assigned zoledronate and 190 assigned placebo. The older trial used a different infusion schedule and counted a wider range of fragility fractures as its main outcome. Its participants, by age and enrollment criteria, started from a different risk profile. It supports a role for zoledronate in reducing fractures in that older population. The schedule and fracture counts from one study cannot be carried directly into the other. Randomized trial in older women with osteopenia
For a woman in her 50s, the relevant starting risk may depend on details that a single T-score cannot capture. A previous fracture, certain medications and other medical conditions can all change how closely someone resembles the women in this trial. Even if the relative benefit were similar across two groups, the group starting with the smaller chance of fracture would generally stand to avoid fewer fractures per 100 people treated. That is why the 4.8-point difference is best read alongside the trial’s enrollment criteria. It is an estimate for a particular group over a particular decade. Enrollment criteria and subgroup analysis
There are also practical costs to treating early. The U.S. label describes short-term reactions after an infusion, such as fever, muscle aches and flu-like symptoms. It identifies kidney impairment and low calcium as important safety considerations and warns about osteonecrosis of the jaw and atypical fractures of the thigh bone. A trial of roughly a thousand people can detect a difference in a relatively common imaging outcome and still give limited information about very rare harms. That uncertainty becomes more consequential when considering treatment for people whose chance of a fracture is already small. FDA prescribing information
The trial covers much of the transition from a participant’s mid-50s to her mid-60s. Whether starting earlier changes fracture risk decades later is a separate question. Bolland’s team reported starting an extension to compare the effects of different infusion schedules for up to 20 years. Follow-up on that scale may help clarify how long the separation between groups persists and whether it translates into a clearer difference in clinically recognized fractures as participants get older. For now, the most direct evidence supports a reduction in new vertebral fractures seen on X-rays over ten years with the two-infusion strategy studied. Extension plans and discussion
Frequently asked questions
Did the trial include women with normal bone density?
Yes. The eligible T-score range included some readings considered normal and some in the osteopenia range.
Can one infusion protect the spine for ten years?
The results suggest a possible benefit. The single-infusion group had fewer X-ray-detected spine fractures than placebo, but the primary comparison fell short of the trial’s statistical threshold.
Did this trial establish a benefit for hip fractures specifically?
The clearest finding concerned vertebral fractures on X-rays. The trial did not establish a hip-specific benefit for these women.
This article summarises published research and is not medical advice. Consult your healthcare provider before changing your routine.
Frequently Asked Questions
Did the trial include women with normal bone density?
Can one infusion protect the spine for ten years?
Did this trial establish a benefit for hip fractures specifically?
Sources
- The New England Journal of Medicine — Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age(2026)
- The Journal of Clinical Endocrinology & Metabolism — Secondary Analyses of a Randomized Zoledronate Trial(2026)
- The New England Journal of Medicine — Fracture Prevention with Zoledronate in Older Women with Osteopenia(2026)
- U.S. Food and Drug Administration — Reclast Prescribing Information(2026)
Stay Updated on Longevity Science
Weekly research digests. No spam, unsubscribe anytime.
Related Articles

Arterial Stiffness and Vascular Age: A Longevity Evidence Guide
Understand arterial stiffness vascular age longevity links, key studies, measurement limits, and evidence-based lifestyle implications for healthy aging.
11 min read
Arterial Stiffness and Vascular Aging: What the Evidence Shows
Explore arterial stiffness vascular aging, how vessels change over time, what pulse wave velocity studies show, and practical ways evidence may inform prevention.
10 min read
Aspirin May Increase Bleeding Without Extending Disability-Free Life
In older adults without cardiovascular disease, aspirin trials suggest bleeding risks may outweigh preventive benefits, with no demonstrated gain in independent life.
8 min read